← Scroll for more →
Financial Statements — LGCB
Balance Sheet
(in millions USD)| Metric | Q4 2025 | Q2 2025 | Q4 2024 | Q4 2023 |
|---|---|---|---|---|
| Cash & Equivalents | 0.73 | 0.33 | 2.00 | 1.11 |
| Accounts Receivable | 4.97 | 6.41 | 6.30 | 2.01 |
| Inventory | 0.00 | 0.04 | 0.07 | 0.68 |
| Total Current Assets | 20.72 | 19.02 | 11.95 | 9.65 |
| Property, Plant & Equipment | 0.22 | 0.05 | 0.09 | 0.16 |
| Total Non-current Assets | 0.63 | 0.57 | 0.74 | 0.99 |
| Total Assets | 21.35 | 19.58 | 12.69 | 10.63 |
| Accounts Payable | 0.05 | 0.32 | 0.62 | 1.14 |
| Short-term Debt | -- | 0.03 | 0.03 | 0.10 |
| Total Current Liabilities | 4.08 | 11.57 | 4.39 | 4.70 |
| Long-term Debt | 0.82 | 0.98 | 1.27 | 2.53 |
| Total Non-current Liabilities | 0.93 | 1.07 | 1.28 | 2.44 |
| Total Liabilities | 5.02 | 12.64 | 5.67 | 7.14 |
| Retained Earnings | (5.75) | (1.47) | 1.61 | 2.05 |
| Total Stockholder Equity | 16.34 | 6.94 | 7.02 | 3.50 |
← Scroll for more columns →
Income Statement
(in millions USD) (except per-share rows)| Metric | Q2 2025 |
|---|---|
| Total Revenue | 3.50 |
| Cost of Revenue | 0.80 |
| Gross Profit | 2.70 |
| Research & Development | 0.27 |
| Selling, General & Admin | 3.90 |
| Total Operating Expenses | 4.34 |
| Operating Income | (1.64) |
| Pretax Income | (2.75) |
| Tax Provision | 0.34 |
| Net Income | (3.09) |
| Basic EPS | (0.90) |
| Diluted EPS | (0.90) |
← Scroll for more columns →
Cash Flow Statement
(in millions USD)| Metric | Q2 2025 |
|---|---|
| Operating Cash Flow | (1.74) |
| Investing Cash Flow | (8.74) |
| Financing Cash Flow | 8.74 |
← Scroll for more columns →